Personalized digital reminiscence therapy for older adults with mild neurocognitive disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants will use a conversational reminiscence app for 10–15 minutes daily over 25 days, with a primary caregiver helping to add personal memories and optional contributions from other relatives. The study will collect brief questionnaires on apathy, depression, sleep, quality of life, and engagement at baseline and during follow-up visits. The protocol also examines whether in-app reminders alone are enough to encourage regular use without external assistance. This is an observational study conducted at several French university hospital geriatric departments and the sponsor may provide compatible Apple devices if needed.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women over 60 years of age.
* DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes.
* Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28.
* Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both
* Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool.
* Having voluntarily and informedly agreed to participate in the study (signed written consent).
* Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool).
* Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access.
* Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group.
* Subjects covered by a social security scheme.

Exclusion Criteria:

* Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD.
* Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder).
* Major hearing or visual impairments.
* History of premorbid intellectual disability.
* Patients under guardianship, conservatorship, or legal protection.
* Patients who have already used the Lilia app
* Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study.
* Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit.

Where it's running

• CHU Angers, Service médecine gériatrique.
  Angers, France Recruiting
• Limoges University Hospital Center - Dupuytren Hospital], Geriatric medicine department
  Limoges, France Recruiting
• Centre Hospitalier Universitaire de Nice - Institut Claude Pompidou, Centre Mémoire de Ressources et de Recherches (CM2R)
  Nice, France Recruiting
• CHU DE TOURS, Pôle Vieillissement, Hôpital Bretonneau.
  Tours, France Recruiting
• APHP Hôpitaux universitaires Paris centre.
  Paris, France Not yet recruiting

Study contacts

• Study coordinator: Peter MARKUS
• Email: peter@kompanioncare.com
• Phone: +36303621811

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Robotic technologies to reduce apathy in dementia

  This project will test whether two different home-based robotic programs can help people with mild cognitive impairment or dementia who have apathy become more motivated and engaged compared with standard occupational therapy.

  Recruiting at 2 sites University of Modena and Reggio Emilia · Milan, Italy and 1 other locations · NCT07404410

• Brain stimulation plus methylphenidate for apathy in Alzheimer's

  This trial will test whether combining short sessions of noninvasive brain stimulation (intermittent theta burst) with methylphenidate can reduce apathy in people with Alzheimer's disease or mixed Alzheimer's/vascular dementia.

  Recruiting Phase 2 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT07279740

• Immediate vs progressive standing dual-task training for older adults with mild to moderate cognitive impairment

  This study tests whether starting with immediate standing dual-task training is better or worse than progressively increasing the difficulty for older adults with mild to moderate cognitive impairment.

  Recruiting Shifa Tameer-e-Millat University · Islamabad, Capital · NCT07764250

• Understanding risk factors for cognitive problems in people with coronary heart disease

  In people with coronary heart disease, this study tests how metabolic factors and imaging features relate to cognitive impairment.

  Recruiting Beijing Anzhen Hospital · Beijing, China · NCT07657624

• IRL757 for treating apathy in Parkinson's disease.

  This study will test whether the medication IRL757 is safe, easy to tolerate, and helps reduce apathy in people aged 50–90 with Parkinson's disease.

  Recruiting at 12 sites Phase 1/2 Integrative Research Laboratories AB · Pleven and 13 other locations · NCT07461220

• Accelerated brain stimulation for apathy in Parkinson's disease

  This pilot will see if an accelerated form of intermittent theta-burst brain stimulation can reduce apathy in people with Parkinson's disease.

  Recruiting Medical University of South Carolina · Charleston, South Carolina · NCT07399496

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.